Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037358 · ClinicalTrials.gov registry record · Phase 2
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT04037358 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 64 participants.
The verdict
NCT04037358, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223. We are looking to determine the progression-free survival of men who have oligometastatic prostate cancer with at least one bone metastasis with stereotactic ablative radiation therapy (SABR) versus SABR + Radium-223.
Interventions
- DRUG Radium-223
- RADIATION stereotactic ablative radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2025-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04037358
The ClinicalTrials.gov registry entry for NCT04037358 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radium-223 is the first listed.
NCT04037358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04037358 about?
NCT04037358 is a clinical study titled "RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers". This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223. We are looking to determine the progression-free survival of men who have oligometastatic prostate ...
What is the current status of trial NCT04037358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2019-08-09. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT04037358?
The interventions under investigation include: Radium-223 (DRUG), stereotactic ablative radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT04037358?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.